Free tool
FAERS Monitor: Adakveo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761128 or its brand name (Adakveo, Crizanlizumab-Tmca). Reports on generic versions are filed under their own applications.
Reports
1,397
Serious
759
54% of reports
Hospitalization
572
Death reported
55
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- sickle cell anaemia with crisis364
- pain353
- back pain151
- infusion related reaction131
- arthralgia95
- pain in extremity89
- chest pain81
- nausea80
- drug ineffective79
- pyrexia76
- headache71
- fatigue68
- acute chest syndrome52
- haemoglobin decreased51
- product dose omission issue44
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 4 |
| 2020 | 343 |
| 2021 | 426 |
| 2022 | 331 |
| 2023 | 114 |
| 2024 | 113 |
| 2025 | 45 |
| 2026 | 21 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,762 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute chest syndromeSignal | 52 | 947.6 | 719.6 | 45,376 |
| sickle cell anaemia with crisisSignal | 364 | 355.9 | 325.4 | 125,612 |
| infusion related reactionSignal | 131 | 29.8 | 25.3 | 3,623 |
| back painSignal | 151 | 9.8 | 8.4 | 1,196 |
| painSignal | 353 | 8.7 | 7.9 | 2,453 |
| haemoglobin decreasedSignal | 51 | 7.5 | 5.7 | 281 |
| chest painSignal | 81 | 6.6 | 5.3 | 381 |
| pain in extremitySignal | 89 | 4.5 | 3.7 | 246 |
| arthralgiaSignal | 95 | 3.4 | 2.8 | 165 |
| pyrexiaSignal | 76 | 3.3 | 2.7 | 122 |
| product dose omission issueSignal | 44 | 2.3 | 1.7 | 30 |
| headache | 71 | 1.7 | 1.4 | 21 |
| nausea | 80 | 1.5 | 1.2 | 14 |
| fatigue | 68 | 1.3 | 1.0 | 5 |
| drug ineffective | 79 | 0.9 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.